COX-2, c-KIT and HER-2/neu expression in uterine carcinosarcomas: prognostic factors or potential markers for targeted therapies?

Raspollini, Maria Rosaria; Susini, Tommaso; Amunni, Gianni; Paglierani, Milena; Taddei, Antonio; Marchionni, M; Scarselli, Gianfranco; Taddei, Gian Luigi

doi:10.1016/j.ygyno.2004.09.050

Cited by 58 publications

(36 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The expression c-KIT for example, has been demonstrated in MMMTs (15)(16)(17)(18), but as this protein expression is not associated with KIT-activating mutation in exons 11 or 17, patients with uterine carcinosarcomas are not suitable candidates for treatment with imatinib (19). Similarly, immunohistochemical expression of HER-2 has been reported in a minority of uterine carcinosarcomas (20,21).…”

Section: Discussionmentioning

confidence: 99%

GHRH Receptor Expression in Malignant Mixed Müllerian Tumors

Mackrides

Ganjei‐Azar

Perez

et al. 2016

International Journal of Gynecological Pathology

View full text Add to dashboard Cite

Malignant mixed Müllerian tumors (MMMTs) are aggressive malignant neoplasms with a high recurrence rate and poor prognosis. Despite advances in adjuvant therapies in recent years, the prognosis of these tumors has not improved. Growth hormone-releasing hormone (GHRH) is produced by a variety of malignant tumors and acts as a growth factor in an autocrine/paracrine manner. Its function requires the presence of its receptors to exert its effects on neoplastic cells. In this study, we evaluated the expression of GHRH receptors (GHRH-R) in a group of MMMTs. Thirty-one examples of MMMTs from endometrium, ovary, uterine tube, and pelvic peritoneum were retrieved from the files of Department of Pathology at the University of Miami, Jackson Memorial Hospital. Immunohistochemistry for GHRH-R was performed on paraffin sections and the staining results were evaluated separately in both epithelial and mesenchymal components of each tumor. The presence of pituitary type growth hormone-releasing hormone receptor mRNA and that of its biologically active splice variant were also evaluated by RT-PCR in 6 of the tumors. Positive immunohistochemical reaction for GHRH-R was detected in 30 tumors (96%). The epithelial and sarcomatous components were positive in 30 (96%), whereas one endometrial tumor was negative in both components. The mRNA for GHRH-R and its splice variant was found in all 6 tested tumors. This study shows that GHRH-R is expressed by the majority of MMMTs in both epithelial and mesenchymal components. This finding could potentially serve as a basis for therapeutic approaches using synthetic peptide antagonists of GHRH-R that have shown significant efficacy with minimal side effects in experimental models.

show abstract

Section: Discussionmentioning

confidence: 99%

GHRH Receptor Expression in Malignant Mixed Müllerian Tumors

Mackrides

Ganjei‐Azar

Perez

et al. 2016

International Journal of Gynecological Pathology

View full text Add to dashboard Cite

show abstract

“…HER-2, EGFR, KIT) in some cases of CS, suggesting potential targets for therapeutic intervention in subgroups of CS [9][10][11][12][13][14]. However, serum markers have yet to be identified and evaluated for uterine carcinosarcoma.…”

Section: Introductionmentioning

confidence: 99%

Serum CA125 predicts extrauterine disease and survival in uterine carcinosarcoma

Huang

Chiu

Gebb

et al. 2007

Gynecologic Oncology

View full text Add to dashboard Cite

Objective-The purpose of this study was to determine the clinical utility of CA125 measurement in patients with uterine carcinosarcoma (CS).Methods-Ninety-five consecutive patients treated for CS at a single institution were identified. All 54 patients who underwent preoperative CA125 measurement were included in the study. Data were abstracted from the medical records. Tests of association between preoperative CA125 and previously identified clinicopathologic prognostic factors were performed using Fisher's exact test and Pearson chi-square test. To evaluate relationship of CA125 elevation and survival, a Cox proportional hazard model was used for multivariate analysis, incorporating all of prognostic factors identified by univariate analysis. Conclusion-Preoperative CA125 elevation is a marker of extrauterine disease and deep myometrial invasion in patients with uterine CS. Postoperative CA125 elevation is an independent prognostic factor for poor survival. These findings indicate that CA125 may be a clinically useful serum marker in the management of patients with CS. Results-Preoperative

show abstract

“…1,14Y16 Only 2 studies assessed the effect of COX-2 expression on survival, and as in other gynecologic cancers, the results are conflicting. 1, 15 Raspollini et al 15 in a series of 24 patients found an association with vascular space involvement and with disease-free interval but, paradoxically, no association with stage. However, in contrast to our previous study 1 and to the present study of mature survival data, their patients with COX-2 expression showed significantly poorer survival.…”

Section: Discussionmentioning

confidence: 96%